GILD

MKT CAP:$162B

Gilead Sciences, Inc.

Market Cap

$162B

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NASDAQ

Healthcare·Drug Mfg.·🇺🇸·NASDAQ

Stock Price

$130.29+$8.69 (+7.15%)

Apr 24, 2026

Company Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Ode...

CEO

Daniel O'Day

IPO Date

Jan 22, 1992

Website

www.gilead.com

Key Metrics TTM

Revenue

$29.4B

+2.4% YoY

Net Income

$8.5B

EPS (Diluted)

$6.77

Free Cash Flow

$9.5B

Revenue / Share

$23.50

Gross Margin

80.8%

Operating Margin

37.4%

Net Margin

28.9%

FCF Margin

32.1%

P/S

5.5x

P/E

19.0x

Earnings Reports

FY 2025

Feb 24, 2026

$29.4B+2.4%EPS $6.78

Q4 2025

Feb 24, 2026

$7.9B+4.7%EPS $1.74

Q3 2025

Nov 7, 2025

$7.8B+3.0%EPS $2.43

Q2 2025

Aug 7, 2025

$7.1B+1.8%EPS $1.56

Q1 2025

May 7, 2025

$6.7B-0.3%EPS $1.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 20	$5.1B	$4.1B	-$3.0B
Q4 20	$7.4B	$6.0B	$2.7B
Q1 21	$6.4B	$5.1B	$2.9B
Q2 21	$6.2B	$4.8B	$2.2B
Q3 21	$7.4B	$6.2B	$3.8B
Q3 22	$7.0B	$5.6B	$2.8B
Q4 22	$7.4B	$6.0B	$2.3B
Q3 23	$7.0B	$5.5B	$2.6B
Q1 24	$6.7B	$5.1B	-$4.3B
Q2 24	$7.0B	$5.4B	$2.6B
Q3 24	$7.5B	$6.0B	$888M
Q4 24	$7.6B	$6.0B	$2.5B
Q1 25	$6.7B	$5.1B	$2.2B
Q2 25	$7.1B	$5.6B	$2.5B
Q3 25	$7.8B	$6.2B	$3.3B
Q4 25	$7.9B	$6.9B	$3.0B

Valuation

Quarter	P/S	P/E
Q2 20	4.2x	1299.6x
Q4 20	3.0x	—
Q1 21	3.3x	31.5x
Q2 21	3.4x	58.1x
Q3 21	3.2x	12.0x
Q3 22	2.9x	10.2x
Q4 22	3.8x	14.1x
Q3 23	3.2x	11.3x
Q1 24	3.2x	63.2x
Q2 24	3.0x	67.7x
Q3 24	3.7x	119.3x
Q4 24	4.0x	239.2x
Q1 25	4.9x	23.4x
Q2 25	4.8x	21.8x
Q3 25	4.8x	17.3x
Q4 25	5.3x	18.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 20	$2.6B	$2.4B
Q4 20	$1.9B	$1.7B
Q1 21	$2.6B	$2.4B
Q2 21	$2.3B	$2.2B
Q3 21	$3.3B	$3.1B
Q3 22	$2.9B	$2.7B
Q4 22	$2.6B	$2.4B
Q3 23	$1.8B	$1.6B
Q1 24	$2.2B	$2.1B
Q2 24	$1.3B	$1.2B
Q3 24	$4.3B	$4.2B
Q4 24	$3.0B	$2.8B
Q1 25	$1.8B	$1.7B
Q2 25	$827M	$720M
Q3 25	$4.1B	$4.0B
Q4 25	$3.3B	$3.1B

Capital Expenditures

Quarter	CapEx
Q2 20	$143M
Q4 20	$181M
Q1 21	$165M
Q2 21	$119M
Q3 21	$139M
Q3 22	$157M
Q4 22	$181M
Q3 23	$122M
Q1 24	$105M
Q2 24	$130M
Q3 24	$141M
Q4 24	$147M
Q1 25	$104M
Q2 25	$107M
Q3 25	$147M
Q4 25	$205M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 20	-2.6%	+167.0%
Q4 20	+30.5%	+46.5%
Q1 21	+14.6%	-50.1%
Q2 21	+5.7%	-17.0%
Q3 21	+44.3%	-56.0%
Q3 22	-5.1%	-11.8%
Q4 22	+15.0%	+45.0%
Q3 23	+13.4%	+11.5%
Q1 24	-9.9%	+207.6%
Q2 24	-1.3%	+2.5%
Q3 24	+2.1%	+30.0%
Q4 24	+7.4%	+15.6%
Q1 25	-0.3%	-59.8%
Q2 25	+1.8%	+6.9%
Q3 25	+3.0%	-33.3%
Q4 25	+4.7%	-3.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 20	$168M	3.3%
Q4 20	$161M	2.2%
Q1 21	$139M	2.2%
Q2 21	$166M	2.7%
Q3 21	$171M	2.3%
Q3 22	$168M	2.4%
Q4 22	$174M	2.4%
Q3 23	$202M	2.9%
Q1 24	$187M	2.8%
Q2 24	$210M	3.0%
Q3 24	$216M	2.9%
Q4 24	$222M	2.9%
Q1 25	$209M	3.1%
Q2 25	$225M	3.2%
Q3 25	$230M	3.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 20	$1.3B	—	—	$1.2B
Q4 20	$1.6B	—	—	$1.7B
Q1 21	$1.1B	—	—	$1.1B
Q2 21	$1.1B	—	—	$1.4B
Q3 21	$1.1B	—	—	$1.2B
Q3 22	$1.1B	—	—	$1.2B
Q4 22	—	—	—	$2.0B
Q3 23	$1.5B	—	—	$1.3B
Q1 24	$1.5B	$632M	$743M	—
Q2 24	$1.4B	$572M	$805M	—
Q3 24	$1.4B	$442M	$968M	—
Q4 24	$1.6B	$992M	$869M	—
Q1 25	$1.4B	$505M	$753M	—
Q2 25	$1.5B	$501M	$864M	—
Q3 25	$1.3B	$528M	$829M	—
Q4 25	$1.6B	—	—	$1.8B

Revenue Segments

Quarter	Cell Therapy Products, Total Cell Therapy Product Sales	Hepatitis B Virus / Hepatitis Delta Virus Product	Other Hepatitis C Virus Products	Other Products, Total Other product sales	Products, Other HIV	Trodelvy	Veklury	Liver Disease
Q3 21	$444M	$247M	$52M	$245M	$4.2B	$101M	$1.9B	—
Q3 22	$796M	$264M	$44M	$200M	$4.5B	$180M	$925M	—
Q3 23	$973M	$269M	$38M	$216M	$4.7B	$283M	$636M	—
Q1 24	$960M	—	—	$224M	$4.3B	$309M	$555M	—
Q3 24	$970M	—	—	$201M	$5.1B	$332M	$692M	—
Q1 25	$464M	—	—	$209M	$4.6B	$293M	$302M	$758M
Q2 25	$577M	—	—	$202M	$5.1B	$364M	$121M	$795M

Revenue by Geography

Quarter	Europe	Other International	United States
Q2 20	$786M	$573M	$3.8B
Q4 20	$1.4B	$657M	$5.3B
Q1 21	$1.3B	$827M	$4.3B
Q2 21	$1.2B	$792M	$4.2B
Q3 21	$1.0B	$881M	$5.5B
Q3 22	$1.1B	$1.0B	$4.9B
Q4 22	$1.1B	$1.0B	$5.3B
Q3 23	$1.0B	$993M	$5.0B
Q1 24	$1.2B	$894M	$4.6B
Q2 24	$1.1B	$879M	$4.9B
Q3 24	$1.2B	$929M	$5.5B
Q4 24	$1.2B	$827M	$5.6B
Q1 25	$1.1B	$915M	$4.7B
Q2 25	$1.2B	$842M	$5.3B
Q3 25	$1.6B	$933M	$5.3B
Q4 25	$1.2B	$813M	$5.7B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$4.3B	$1.0B	$5.3B
Q2 22	$4.7B	$924M	$5.7B
Q3 22	$4.7B	$961M	$5.7B
Q4 22	$5.4B	$973M	$6.4B
Q1 23	$4.9B	$936M	$5.9B
Q2 23	$5.7B	$963M	$6.7B
Q3 23	$5.7B	$1.2B	$6.9B
Q4 23	$6.1B	$2.3B	$8.3B
Q1 24	$4.7B	$1.3B	$6.1B
Q2 24	$2.8B	$1.4B	$4.2B
Q3 24	$5.0B	$1.7B	$6.7B
Q4 24	$10.0B	$1.6B	$11.6B
Q1 25	$7.9B	$0	$7.9B
Q2 25	$5.1B	$69M	$5.2B
Q3 25	$7.3B	$19M	$7.3B
Q4 25	$7.6B	$3.0B	$10.6B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 20	1.25B	-1.4%	-2.2%
Q4 20	1.26B	+0.3%	-1.4%
Q1 21	1.26B	+0.2%	-0.4%
Q2 21	1.26B	-0.2%	-1.0%
Q3 21	1.26B	+0.2%	+0.6%
Q3 22	1.26B	-0.1%	+0.2%
Q4 22	1.26B	+0.2%	+0.2%
Q3 23	1.26B	-0.6%	-0.2%
Q1 24	1.25B	-0.8%	-1.2%
Q2 24	1.25B	+0.3%	-0.8%
Q3 24	1.25B	+0.2%	-0.8%
Q4 24	1.26B	+0.4%	+0.2%
Q1 25	1.26B	0.0%	+1.0%
Q2 25	1.25B	-0.3%	+0.3%
Q3 25	1.25B	-0.1%	0.0%
Q4 25	1.25B	-0.1%	-0.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 20	$435.8K	12K
Q4 20	$545.7K	14K
Q1 21	$472.3K	14K
Q2 21	$457.1K	14K
Q3 21	$545.7K	14K
Q3 22	$489.0K	14K
Q4 22	$434.6K	17K
Q3 23	$414.7K	17K
Q1 24	$371.4K	18K
Q2 24	$386.3K	18K
Q3 24	$419.2K	18K
Q4 24	$430.1K	18K
Q1 25	$378.8K	18K
Q2 25	$402.3K	18K
Q3 25	$441.4K	18K
Q4 25	$466.2K	17K

Revenue / Employee